返回
Liminatus Pharma Inc（LIMN）價格
LIMN 股價走勢圖
LIMN 收益
Liminatus Pharma Inc
$0.37
-22.49%
$-0.1
收盤價：Feb 13, 16:00:00 GMT-5
$0.4
6.64%
$0.02
盤前：Feb 17, 04:29:32 GMT-5
關鍵數據
前收市價
$0.4851
開盤價
$0.4924
當日範圍
$0.3519 - $0.4995
52週區間
$0.351 - $33.66
交易量
6.6M
平均成交量
7.4M
每股盈餘 (TTM)
-0.20
股息收益率
--
市值
$10.8M
什麼是 LIMN？
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.